Michael Adenaike, MD
Cardiovascular Disease · Doylestown, PANPI 1700049939
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,364 of the $14,198 with a category attached, or 73.0%. Johnson & Johnson accounts for 77.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $11,541 and has fallen 97.2% since, to $321 in 2025.
Across 200 payments — averaging $70.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$11K
- Novartis$783
- Merck$481
- Boehringer Ingelheim$237
- E.r. Squibb & Sons, L.L.C.$227
- Pfizer$219
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$10,36473%
- Travel & lodging$1991%
- Food & beverage$3,62326%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $11,017 |
| Novartis | 52 | $783 |
| Merck | 21 | $481 |
| Boehringer Ingelheim | 9 | $237 |
| E.r. Squibb & Sons, L.L.C. | 15 | $227 |
| Pfizer | 15 | $219 |
| AstraZeneca | 11 | $204 |
| Amarin Pharma, Inc. | 11 | $156 |
| Amgen | 8 | $154 |
| Novo Nordisk | 7 | $139 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $139 |
| Heartflow, Inc. | 1 | $129 |
| Sanofi-aventis U.S. LLC | 6 | $107 |
| Lantheus Medical Imaging, Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Bayer | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Altathera Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,198 in reported general payments places this provider in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 443 | $471,951 |
| XareltoRivaroxaban | 118 | $141,340 |
| JardianceEmpagliflozin | 62 | $64,839 |
| EntrestoSacubitril/Valsartan | 47 | $50,024 |
| FarxigaDapagliflozin Propanediol | 32 | $29,385 |
| Repatha SureclickEvolocumab | 22 | $25,706 |
| MultaqDronedarone Hcl | 12 | $15,618 |
| Dofetilide | 38 | $10,540 |
| Metoprolol Succinate | 584 | $9,994 |
| Fenofibrate | 40 | $8,148 |
| Atorvastatin Calcium | 560 | $7,110 |
| Ezetimibe | 286 | $6,427 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 173 | $4,619 |
| Valsartan | 97 | $3,645 |
| Rosuvastatin Calcium | 265 | $3,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $219 | $471,951443 claims |
| Johnson & JohnsonXarelto | $11,017 | $141,340118 claims |
| Boehringer IngelheimJardiance | $237 | $64,83962 claims |
| NovartisEntresto | $783 | $50,02447 claims |
| AstraZenecaFarxiga | $204 | $29,38532 claims |
| Sanofi-aventis U.S. LLCMultaq | $107 | $15,61812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Doylestown
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
- Rajesh DaveCamp Hill$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.